Here are five developments in orthobiologics since Sept. 5.
1. Lenoss Medical’s OsteoPearl biologic allograft for spine earned two new U.S. patents and one European patent.
2. Keensight Capital, a private equity manager, has acquired a majority stake in regenerative medtech company Isto Biologics from Thompson Street Capital Partners.
3. The American Academy of Orthopaedic Surgeons’ updated rotator cuff guideline strongly recommends the use of biologic implants during repair — a move that could reshape practice patterns and patient access.
4. Researchers at Columbia-based University of Missouri are developing bioactive materials to replace metal rods and screws traditionally used in spinal fusion surgeries.
5. Kuros Biosciences’ released its MagnetOS minimally invasive spine delivery system in a full commercial launch.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
